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AbstrAct
Osterix (Osx) is an essential transcription factor involved in osteoblast 
differentiation and bone formation. The precise molecular mechanisms of the 
regulation of Osx expression are not fully understood. In the present study, we 
found that in cells, both endogenous and exogenous Osx protein increased after 
treatment with histone deacetylase inhibitors Trichostatin A and hydroxamic acid. 
Meanwhile, the results of immunoprecipitation indicated that Osx was an acetylated 
protein and that the CREB binding protein (CBP), and less efficiently p300, acetylated 
Osx. The interaction and colocalization of CBP and Osx were demonstrated by Co-
immunoprecipitation and immunofluorescence, respectively. In addition, K307 and 
K312 were identified as the acetylated sites of Osx. By contrast, HDAC4, a histone 
deacetylase (HDAC), was observed to interact and co-localize with Osx. HDAC4 
was demonstrated to mediate the deacetylation of Osx. Moreover, we found that 
acetylation of Osx enhanced its stability, DNA binding ability and transcriptional 
activity. Finally, we demonstrated that acetylation of Osx was required for the 
osteogenic differentiation of C2C12 cells. Taken together, our results provide evidence 
that CBP-mediated acetylation and HDAC4-mediated deacetylation have critical roles 
in the modification of Osx, and thus are important in osteoblast differentiation.
IntroductIon
Bone remodeling is a dynamic process that is 
maintained by the balance between osteoblast and 
osteoclast activity. Disruption of this balance will lead 
to certain pathological states, such as osteoporosis. 
Differentiation of osteoblasts from mesenchymal stem 
cells is controlled by a variety of transcription factors and 
signal molecules, such as ATF4, Runx2, Osterix (Osx or 
Sp7) and bone morphogenetic proteins (BMPs), fibroblast 
growth factors (FGFs), insulin-like growth factor 1 
(IGF1) [1]. Most importantly, Osx is a critical regulator 
for the differentiation of pre-osteoblasts into functional 
osteoblasts [2].
Osx, which belongs to the Sp family, was identified 
as a C2H2-type zinc-finger-containing transcription 
factor in 2002 [3]. Osx-null mice died immediately after 
birth, with a complete absence of intramembranous 
and endochondral bone formation [3]. Mice with 
osteoblast-specific ablation of Osx were viable, but 
exhibited an osteopenia phenotype [4]. Mice with an 
Osx haploinsufficiency in their chondrocytes exhibited 
delayed growth of both trabecular and cortical bones 
[5]. In humans, genetic polymorphisms in the Osx gene 
locus are associated with low bone mineral density [6, 7]. 
Moreover, a frameshift mutation in Osx was reported to 
lead to osteogenesis imperfecta, revealing an important 
role of Osx in human bone development [8]. Therefore, 
determination of the regulatory mechanism of Osx 
expression could provide new insights into osteogenic 
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differentiation and the treatment of bone related diseases.
Osx expression and activity are regulated by 
growth factors, transcription factors, protein interactions 
and epigenetics. For instance, BMP2 stimulates Osx 
expression in a Runx2-dependent or independent manner 
[9-11]. XBP1 (X-box binding protein 1), Runx2, Runx3 
and Prx1 (Peroxiredoxin 1) positively or negatively 
regulate the transcription of Osx [12-15]. Additionally, 
NFATc1, p300, Brg1 and NO66 regulate the transcriptional 
activity of Osx via protein interactions [16-18]. Moreover, 
Osx expression can be regulated by certain miRNAs 
(microRNAs) via a post-transcriptional mechanism, such 
as miR-637, miR-214 and miR-143 [19-21]. Furthermore, 
the transcriptional activity and/or stability of Osx are 
regulated by post-translational modifications (PTMs), 
including phosphorylation and ubiquitination [17, 22-23]. 
Although these findings indicated significant progress, 
the exact regulatory mechanisms of Osx remain to be 
explored.
Lysine acetylation was first discovered on histones 
in 1968 [24]. Two counteracting enzymes, histone 
acetyltransferases (HATs) and histone deacetylases 
(HDACs), are responsible for acetylation catalysis [25]. 
HATs are responsible for adding an acetyl group from 
acetyl-CoA to an ε-amino group of certain lysine side 
chains of proteins. HDACs are responsible for removing 
acetyl groups and maintenance of the equilibrium of lysine 
acetylation. In addition to histones, many non-histone 
proteins, including transcription factors such as p53, 
GATA-1 and Runx2, have been identified as substrates 
of acetyltransferases [26-28]. HATs comprise three 
families: MYST, GNAT and p300/CBP [29]. CBP and 
p300 share ∼90% homology in their HAT domains and 
∼93% homology in the bromodomain. Except for these 
two highly conserved domains, the homologies of other 
regions are much lower [30]. HDACs are classified into 
four groups [31]. In humans, HDAC4 belongs to class II, 
which is located in both the nucleus and cytoplasm. Lysine 
acetylation of non-histone proteins plays critical roles in 
the regulation of mRNA stability, DNA binding ability, 
transcriptional activity, cellular localization, protein 
stability, enzyme activity, protein–protein and protein–
DNA interactions [24, 32]. As a key regulator of cellular 
events, protein acetylation has received more attention 
recently.
In the present study, we evaluated the effects of 
acetylation on the function of Osx. We demonstrated 
that Osx is acetylated and that CBP is the major 
HAT contributing to Osx acetylation. In addition, we 
identified K307 and K312 as the acetylated sites of Osx 
and demonstrated that CBP interacted and co-localized 
with Osx. In addition, we demonstrated that HDAC4 is 
involved in the deacetylation of Osx. Functionally, we 
found that acetylation of Osx enhances its stability, DNA 
binding ability and transcriptional activity. Finally, we 
demonstrated that acetylation of Osx is required for the 
osteogenic differentiation of C2C12 cells. Taken together, 
our results provide the first evidence that CBP-mediated 
acetylation and HDAC4 mediated deacetylation have 
critical roles in the modification of Osx, and are thus 
important in osteoblast differentiation.
results
the osx protein is acetylated
To determine whether acetylation modification is 
involved in the regulation of Osx, we firstly examined the 
effects of HDAC inhibitors (HDACI) on the expression 
of Osx. Saos-2 cells, which express endogenous Osx, or 
HEK 293T cells, which overexpressed Flag-tagged Osx, 
were treated by Trichostatin A (TSA) or hydroxamic acid 
(SAHA). Western blotting showed that the endogenous 
Osx protein increased in a dose dependent manner after 
TSA or SAHA treatment (Figure 1A). Meanwhile, the 
exogenous Osx protein also increased in a dose dependent 
manner after TSA or SAHA treatment (Figure 1B). 
Moreover, we found that TSA and SAHA treatment had no 
obvious effects on the mRNA levels of Osx (Supplemental 
Figure S1A-D). These results suggest that acetylation 
modification might be involved in the post-translational 
regulation of Osx expression.
To further verify that Osx is acetylated in cells, 
immunoprecipitation (IP) assays with an anti-acetyl-
lysine specific antibody were performed. To overcome the 
problem of the similar molecular weight of Osx and IgG 
(H), we constructed a plasmid that expressed Osx fused 
to GFP (HA-Osx-GFP), and overexpressed it in HEK 
293T cells. As shown in Figure 1C, the acetylated form 
of Osx was detected using the anti-acetyl-lysine specific 
antibody in HEK 293T cells that overexpresssed HA-Osx-
GFP. To determine whether the endogenous Osx protein is 
acetylated, we treated Saos-2 cells with or without TSA 
(60 nM) for 24 h and the cell lysates were then used for 
IP assay. As shown in Figure 1D, the acetylated Osx was 
detected in Saos-2 cells and TSA treatment increased the 
acetylation level of the endogenous Osx. Together, these 
data indicate that Osx is a protein regulated by acetylation.
osx acetylation is mediated by p300/cbP
The above data prompted us to identify the 
histone acetyltransferases that are responsible for Osx 
acetylation. We transfected p300, PCAF, CBP and 
GCN5 expression plasmids, separately, together with the 
HA-Osx-GFP construct into HEK 293T cells. The cell 
lysates were analyzed by immunoblotting to examine 
the Osx protein level. As shown in Figure 2A, both p300 
and CBP increased the Osx protein level, although by 
different amounts, hinting that these two enzymes might 
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Figure 1: the osx protein is acetylated. A. Saos-2 cells were treated with TSA (0, 15, 30, 60 nM) or SAHA (0, 15, 30, 60 nM) for 
24 h. Endogenous Osx protein was detected by western blotting with an anti-Osx antibody. β-Actin served as a loading control. The protein 
levels of Osx in the upper panel were determined by densitometry (lower). b. HEK 293T cells were transfected with Flag-Osx plasmids and 
then treated with TSA (0, 15, 30, 60 nM) or SAHA (0, 15, 30, 60 nM) for 24 h. Exogenous Osx protein was detected by western blotting 
with an anti-Flag antibody. β-Actin served as a loading control. The protein levels of Osx in upper panel were determined by densitometry 
(lower panel). c. HEK 293T cells were transiently transfected with HA-Osx-GFP or HA-GFP expression plasmids. The cell lysates were 
immunoprecipitated with an anti-HA antibody and then blotted with an anti-Acetylated-Lys antibody. HA-Osx-GFP and HA-GFP protein 
were detected by western blotting analysis with an anti-HA antibody. d. Saos-2 cells were treated with or without TSA (60 nM) for 24 h. 
The cell lysates were immunoprecipitated with an anti-Osx antibody (rabbit polyclonal antibody) and then blotted with an anti-Acetylated-
Lysine antibody (mouse monoclonal antibody). Osx protein was detected by western blotting analysis with an anti-Osx antibody. Results 
are shown for one of three independent experiments.
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Figure 2: osx acetylation is mediated by cbP/p300. A. HEK 293T cells were transiently co-transfected with HA-Osx-GFP and 
p300-myc, Flag-PCAF, Flag-CBP-HA, or Flag-GCN5 expression vectors. pcDNA3.1 empty vector co-transfection was used as a control. 
The Osx protein was detected by western blotting with an anti-HA antibody. β-Actin served as a loading control. b. The cell lysates of 
the above-transfected cells were immunoprecipitated with an anti-HA antibody and then blotted with an anti-Acetylated-Lys antibody. 
HA-Osx-GFP protein was detected by western blotting with an anti-HA antibody. c. HEK 293T cells were transiently co-transfected with 
Flag-CBP-HA and HA-Osx-GFP or HA-GFP expression plasmids, the cell lysates were immunoprecipitated with an anti-HA antibody 
and then blotted with an anti-Acetylated-Lys antibody. HA-Osx-GFP and HA-GFP protein were detected by western blotting with an 
anti-HA antibody. d. HEK 293T cells were transiently transfected with HA-Osx-GFP alone or together with the Flag-CBP-HA expression 
plasmid, the cell lysates were immunoprecipitated with an anti-Flag antibody and then blotted with an anti-HA antibody. Flag-CBP-HA and 
HA-Osx-GFP protein were detected by western blotting with an anti-HA antibody. e. HEK 293T cells were transiently transfected with 
Flag-CBP-HA alone or together with HA-Osx expression plasmid, the cell lysates were immunoprecipitated with an anti-Osx antibody and 
then blotted with an anti-Flag antibody. Flag-CBP-HA and HA-Osx protein were detected by western blotting with an anti-HA antibody. 
F. HEK 293T cells were transiently co-transfected with HA-Osx-GFP and Flag-CBP-HA expression plasmids. The localization of Osx 
was visualized as green fluorescence, and CBP was visualized by immunostaining with an anti-Flag antibody (red). Nuclei were visualized 
using 4, 6-diamidino-2-phenylindole (DAPI) staining (blue). Experiments were repeated at least three times.
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be responsible for Osx acetylation. The expressions of 
p300, PCAF, CBP and GCN5 are shown in Supplemental 
Figure S2A. In addition, we found that there was no 
obvious effect of histone acetyltransferases on the mRNA 
expression of Osx (Supplemental Figure S2B). The same 
cell lysates were analyzed with an anti-HA antibody 
for IP and an anti-acetyl-lysine specific antibody for 
immunodetection. The results showed that both CBP 
and p300 increased the level of Osx acetylation (Figure 
2B). However, CBP’s promotion of Osx acetylation was 
much stronger than that of p300 (Figure 2B). To rule out 
the interference of GFP, HA-Osx-GFP or HA-GFP was 
co-transfected with a CBP expression plasmid into HEK 
293T cells followed by an IP assay. As shown in Figure 
2C, acetylated Osx was detected in the lysates of cells 
co-transfected with HA-Osx-GFP and CBP, while no 
acetylated GFP was detected in the lysates of cells co-
transfected with HA-GFP and CBP. Taken together, these 
results suggested that CBP is the major acetyltransferase 
that mediates Osx acetylation.
To test whether CBP interacts with Osx in vivo, 
cell extracts from HEK 293T cells ectopically expressing 
Flag-CBP-HA and HA-Osx-GFP were used in a Flag 
IP assay. After probing the immunocomplexes using 
an anti-HA antibody, the Osx protein was detected in 
CBP immunoprecipitates (Figure 2D). Conversely, CBP 
protein was detected in Osx immunoprecipitates (Figure 
2E). These results revealed an interaction between CBP 
and Osx. Corroborating these data, CBP was observed 
to be co-localized with Osx in the nucleus using 
immunofluorescence staining (Figure 2F).
cbP acetylates osx at K307 and K312
In a previous study, we generated series Osx mutants 
with lysine-to-arginine (K to R) substitutions to identify the 
ubiquitination sites of Osx [22]. Using luciferase reporter 
assays, we found that the K26R, K41R, K45R, K46R, 
Figure 3: Identification of the acetylated site(s) of Osx mediated by CBP. A. HEK 293T cells were transiently co-transfected 
with Flag-CBP-HA and HA-Osx-GFP expression plasmids or K26R, K41R, K45R, K46R, K58R, K230R, K291R, K307R, K312R mutants. 
The cell lysates were immunoprecipitated with an anti-HA antibody and then blotted with an anti-Acetylated-Lys antibody. Flag-CBP-HA 
and HA-Osx-GFP protein were detected by western blotting with an anti-HA antibody. b. HEK 293T cells were transiently transfected with 
HA-Osx-GFP expression plasmid or the K307R, K312R mutants. 24 h after transfection, the cells were treated with or without 60 μM TSA 
for 24 h. The cell lysates were immunoprecipitated with an anti-HA antibody and then blotted with an anti-Acetylated-Lys antibody. HA-
Osx-GFP protein were detected by western blotting with an anti-HA antibody. Experiments were repeated at least three times.
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Figure 4: HdAc4 mediates osx deacetylation. A. HEK 293T cells were transiently transfected with the HA-Osx-GFP expression 
plasmid alone or together with Flag-HDAC1, Flag-HDAC3, Flag-HDAC4, or Flag-HDAC5 expression vectors. The Osx protein was 
detected by western blotting with an anti-HA antibody. β-Actin served as a loading control. b. HEK 293T cells were transiently co-
transfected with Flag-CBP-HA, HA-Osx-GFP and Flag-HDAC4 or not, the cell lysates were immunoprecipitated with an anti-HA antibody 
and then blotted with an anti-Acetylated-Lys antibody. Flag-CBP-HA and Flag-HDAC4 protein were detected by western blotting with 
an anti-Flag antibody. HA-Osx-GFP protein was detected with an anti-HA antibody. c. HEK 293T cells were transiently transfected with 
HA-Osx-GFP alone or together with Flag-HDAC4 expression plasmid, the cell lysates were immunoprecipitated with an anti-Flag antibody 
and then blotted with an anti-HA antibody. Flag-HDAC4 and HA-Osx-GFP protein were detected by western blotting with an anti-Flag 
and anti-HA antibody, respectively. d. HEK 293T cells were transiently transfected with Flag-HDAC4 alone or together with the HA-Osx 
expression plasmid, the cell lysates were immunoprecipitated with an anti-HA antibody and then blotted with an anti-Flag antibody. Flag-
HDAC4 and HA-Osx protein were detected by western blotting with an anti-Flag and anti-HA antibody, respectively. e. HEK 293T cells 
were transiently co-transfected with HA-Osx-GFP and Flag-HDAC4 expression plasmids. The localization of Osx was visualized as green 
fluorescence, the localization of HDAC4 was visualized by immunostaining with an anti-Flag antibody (red). Nuclei were visualized by 
DAPI staining (blue). Experiments were repeated at least three times.
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K58R and K230R mutants increased the transactivation 
activities of Osx; however, K291R, K307R and K312R 
mutants decreased the transactivation activities of Osx 
[22]. Besides providing specific sites for ubiquitination, 
lysine also provides sites for acetylation. To test whether 
the acetylation sites of Osx resided in these nine lysine 
residues, these Osx mutants were co-transfected with the 
CBP expression plasmid into HEK 293T cells. The cell 
lysates were immunoprecipitated with an anti-HA antibody 
and western blotted with an anti-acetyl-lysine antibody. 
As shown in Figure 3A, the acetylation of Osx mediated 
by CBP was decreased markedly in cells transfected with 
the OsxK307R and OsxK312R mutants, indicating that K307 
and K312 are the acetylated sites of Osx. Moreover, TSA 
treatment increased the acetylation level of Osx and had 
little effect on the acetylation level of the OsxK307R and 
OsxK312R mutants (Figure 3B).
HdAc4 mediates osx deacetylation
Lysine acetylation is a reversible protein 
modification, which is controlled by two opposing types 
of enzymes families: HATs and HDACs. We next set out 
to investigate whether any of the HDACs (HDAC1, -3, 
-4, and -5) is capable of deacetylating Osx. As shown in 
Figure 4A, HDAC4 overexpression led to a decrease in 
the Osx protein level, indicating that HDAC4 might be 
involved in the deacetylation of Osx. The expressions 
of HDAC1, -3, -4, and -5 are shown in Supplemental 
Figure S3A. In addition, we found that there was no 
obvious effect of the HDACs on mRNA expression of 
Osx (Supplemental Figure S3B). To further confirm the 
effect of HDAC4 on Osx acetylation, we performed an 
IP assay using cell lysates from HEK 293T transfected 
with CBP and Osx, with or without HDAC4 expression 
plasmids. The results indicated that HDAC4 decreased 
the level of Osx acetylation mediated by CBP (Figure 
4B), providing evidence that HDAC4 mediated Osx 
deacetylation. Furthermore, HEK 293T cells were co-
transfected with Flag-HDAC4 and HA-Osx-GFP or 
HA-Osx expression plasmids, and the cell lysates were 
then analyzed using Co-IP assays. Osx was detected in 
HDAC4 immunoprecipitates (Figure 4C). Conversely, 
HDAC4 was detected in Osx immunoprecipitates (Figure 
4D). In addition, an immunofluorescence staining assay 
showed that HDAC4 co-transfection led to the export 
of Osx from nucleus to the cytoplasm and that HDAC4 
was co-localized with Osx in the cytoplasm (Figure 4E). 
These results revealed that HDAC4 physically interacts 
with Osx.
Acetylation increases the stability of Osx
Our previous studies revealed that Osx is an unstable 
protein and the ubiquitin proteasome pathway is involved 
in the regulation of Osx stability [22]. To assess the effect 
of acetylation on Osx stability, we transfected HEK 293T 
cells with Osx constructs alone or together with CBP 
or HDAC4 expression plasmids and then treated the 
cells with the protein synthesis inhibitor cycloheximide 
(CHX). Compared with Osx transfection alone, CBP 
co-transfection markedly delayed the degradation of 
Osx (Figure 5A). Conversely, HDAC4 co-transfection 
markedly accelerated the degradation of Osx (Figure 
5B). In addition, the stabilities of OsxK307R, OsxK312R and 
OsxK307R-K312R were decreased compared with Osx (WT) 
(Figure 5C). The similar transfection efficiency of the 
OsxK307R, OsxK312R and OsxK307R-K312R expression plasmids 
was confirmed in Supplemental Figure S4.
Acetylation increases the DNA binding activity of 
osx
We then investigated the effect of acetylation on 
the DNA binding activity of Osx. First, we determined 
whether K307 and K312 were conserved between 
different members of the Sp family. As shown in Figure 
6A, K307 is conserved across several members, while 
K312 is not conserved. K307 is just adjacent to the C2H2 
DNA binding domain (from amino acid 309 to 376) and 
K312 is located at the N-terminus of the DNA binding 
domain of Osx (Figure 6A). Electrophoretic mobility 
shift assays (EMSAs) showed that CBP and Flag-Osx 
co-expression (Figure 6B, lane 2) markedly increased 
the DNA binding ability of Osx compared with Flag-Osx 
expression plasmid transfection alone (Figure 6B, lane 
1). A supershift effect was observed by the addition of a 
Flag antibody, indicating the specificity of Osx binding 
(Figure 6B, lane 3). Moreover, the DNA binding activity 
of OsxK307R-K312R was decreased compared with the wild-
type Osx (Figure 6C).
Acetylation increases the transactivation activity 
of Osx and deacetylation of Osx impairs osteoblast 
differentiation
Finally, we examined the effects of acetylation 
on the transactivation activity of Osx and on osteoblast 
differentiation. Using the reporter assay, the luciferase 
activity driven by the Osx binding site was remarkably 
increased by CBP co-expression, and this increase was 
attenuated when the acetylated sites K307 and K312 
were mutated (Figure 7A). Meanwhile, we found that 
CBP alone activated the OC promoter activity (Figure 
7A). The luciferase activity was markedly decreased by 
HADC4 co-expression, and HDAC4 had no obvious effect 
on the luciferase activity when the acetylated sites K307 
and K312 were mutated (Figure 7B). Together, these data 
indicate that acetylation potentiates the transcriptional 
activity of Osx. To confirm this further, we transfected 
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expression plasmids of Osx and CBP, alone or together, 
into preosteoblast cells MC3T3 E1, and the mRNA levels 
of Osx target genes including ALP (alkaline phosphatase), 
BSP (bone sialoprotein), Colla1 (collagen I) and OC 
(osteocalcin) were measured by real-time PCR assays. 
As shown in Figure 7C, CBP co-transfection significantly 
increased the mRNA expressions of ALP, BSP, Colla1 
and OC compared with Osx transfection alone. To explore 
the mechanism by which acetylation of Osx enhances 
its transcription activity, we performed Chromatin 
immunoprecipitation (ChIP) assay. As shown in Figure 
7D, the occupancy of Osx at the chromatin fragments 
of the promoter of ALP, BSP, Col1a1, and OC, was 
significantly increased in MC3T3 E1 cells treated with 
TSA compared to the untreated cells. These data suggest 
that acetylation of Osx enhances its transcription activity 
by increasing its binding to the promoter of the target 
genes.
To evaluate the role of Osx acetylation in 
osteoblastic differentiation further, we transiently 
transfected HA-Osx(WT) or the HA-OsxK307R-K312R 
mutant construct into C2C12 cells, a typical pluripotent 
mesenchymal precursor cell line that has the potential to 
differentiate into osteoblasts, chondroblasts, myoblasts, or 
adipocytes. As shown in Figure 7E, the expressions of the 
marker genes of osteoblast differentiation were obviously 
decreased in C2C12 cells transfected with OsxK307R-K312R 
compared with the cells transfected with Osx(WT). 
Simultaneously, ALP staining and Alizarin Red staining 
(ARS) revealed that the ALP activity and mineralization in 
Figure 5: Acetylation increases the stability of Osx. A. HEK 293T cells were transfected with HA-Osx expression plasmids alone 
or together with Flag-CBP-HA and then treated with 80 µM CHX for the indicated periods. Osx and CBP proteins were detected by western 
blotting with an anti-HA antibody. b. HEK 293T cells were transfected with HA-Osx expression plasmids alone or together with Flag-
HDAC4 and then treated with 80 µM CHX for the indicated periods. Osx and HDAC4 proteins were detected by western blotting with an 
anti-HA and anti-Flag antibody, respectively. c. HEK 293T cells were transfected with HA-Osx-GFP, HA-OsxK307-GFP, HA-OsxK312-GFP 
and HA-OsxK307-K312-GFP expression plasmids, respectively. 48 h after transfection, the Osx protein was detected with an anti-HA antibody. 
β-Actin served as a loading control. Results are shown for one of three independent experiments.
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C2C12 cells transfected with OsxK307R-K312R mutants were 
markedly reduced compared with the cells transfected 
with the Osx(WT) plasmids (Figure 7F). The same results 
were observed in MC3T3 E1 cells (Supplemental Figure 
S5). Taken together, these data proved that acetylation 
increased the Osx transcriptional activity and is required 
for Osx to promote osteoblast differentiation.
dIscussIon
In this study, we presented evidence that acetylation 
plays an important role in the function of Osx. We found 
that the transcriptional coactivator CBP interacts with Osx, 
resulting in acetylation of Osx on two lysine residues in 
its C terminus. Furthermore, HDAC4 interacts with and 
deacetylates Osx. Acetylation of these two lysine residues 
stabilizes Osx and enhances its DNA binding activity and 
transcriptional activity. Moreover, we demonstrated that 
acetylation of lysine 307 and 312 is required for Osx to 
promote osteoblast differentiation.
Although CBP and p300 acetylate and interact 
with overlapping sets of proteins, accumulating evidence 
suggests that CBP and p300 possess discrete functions 
in cells. In mice, heterozygous inactivation of CBP and 
Figure 6: Acetylation increases the DNA binding activity of Osx. A. Evolutionary conservation analysis of the acetylation sites 
in Osx. Schematic representation of Osx, its functional domains, the two acetylated lysine residues that were mutated to arginines and a 
partial polypeptide sequence alignment of Osx with Sp1, Sp3 and Sp4. The highlighted boxes indicate the zinc-finger domain (from amino 
acid 309 to 376). The acetylated lysines are indicated by asterisks. b. Nuclear extracts (NE) from HEK 293T cells transfected with Flag-Osx 
expression plasmid alone or together with Flag-CBP-HA were incubated with a 32P-labeled Osx-binding oligonucleotide (MMP-13 probe) 
in the absence (lane 1 and 2) or presence of anti-Flag antibodies (lane 3). The reaction mixtures were analyzed by EMSA. Osx and CBP 
proteins were detected by western blotting with an anti-Flag antibody. c. Nuclear extracts from HEK 293T cells transfected with HA-Osx-
GFP or HA-OsxK307R-K312R-GFP expression plasmids were incubated in reaction mixtures containing 32P-labeled MMP-13 probe, resolved 
by electrophoreses and visualized by autoradiography. Osx and OsxK307R-K312R proteins were detected by western blotting with an anti-HA 
antibody. Experiments were repeated at least three times.
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p300 led to diverse phenotypes, and neither of them can 
compensate for the loss of the other [33-35]. In humans, 
mutations in the CBP gene have been associated with 
Rubinstein-Taybi syndrome and fetal alcohol syndrome, 
while deficiencies in p300 have been associated with 
multiple cancers [33, 36-37]. We found that Osx was more 
efficiently acetylated by CBP than by p300, confirming the 
hypothesis that CBP and p300 have different functions.
Studies have revealed that HDAC4 is a central 
regulator of chondrocyte hypertrophy and skeletogenesis 
[38, 39]. HDAC4 gene knockout mice showed premature 
ossification. By contrast, overexpression of HDAC4 in 
vivo resulted in inhibition of chondrocyte hypertrophy, 
with delayed ossification. HDAC4 regulates chondrocyte 
hypertrophy and endochondral bone formation by 
interacting with Runx2 and inhibiting its activity [38, 
39]. Our results revealed that HDAC4 interacts with Osx 
and mediates its deacetylation. These data reveal another 
mechanism by which HDAC4 exerts its important roles in 
bone development.
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Like phosphorylation, acetylation is a universal 
modification of proteins [40]. More than 2000 non-
histone proteins, including transcription factors, have 
been identified as acetylated [41]. Acetylation can either 
enhance or decrease the DNA binding and transcriptional 
activity of a transcription factor. For instance, acetylation 
of p53 by p300/CBP promotes its DNA binding and 
transcriptional activity [42-44]. Whereas, acetylation of 
the Yin Yang 1 (YY1) protein by p300/CBP resulted in 
decreased DNA binding [45]. Stimulation or inhibition of 
the activity of a given transcription factor by acetylation 
depends on the site of modification. For example, the 
activities of transcription factor HMG-A1 are stimulated 
by lysine 71 acetylation, while they are inhibited by lysine 
65 acetylation [46, 47]. Generally, if the acetylation sites 
lie in a DNA-binding domain, acetylation will repress 
DNA-binding and if they are adjacent to a DNA-binding 
domain, it may activate DNA binding [48, 49]. Here, we 
identified K307 and K312 as the acetylated sites of Osx. 
K307 is just adjacent to the C2H2 DNA binding domain 
(from amino acid 309 to 376) and K312 is located at 
the N-terminus of the DNA binding domain of Osx. We 
speculated that acetylation increases the DNA binding 
activity of Osx, possibly by altering its conformation. 
Further study is needed to investigate the structural 
changes of Osx after acetylation.
Acetylation can affect protein–protein, protein–
DNA and protein–RNA interactions, as well as subcellular 
distribution and protein stability, by neutralizing the 
positive charge of the lysine side chain or impairing 
Figure 7: Acetylation increases the transactivation activity of Osx and deacetylation of Osx impairs osteoblast 
differentiation. A. HEK 293T cells were transfected with a hOc-Luc reporter, β-gal expression vector and together with or without 
Flag-Osx, HA-OsxK307R-K312R and Flag-CBP-HA expression plasmids. b. HEK 293T cells were transfected with the hOc-Luc reporter, β-gal 
expression vector, and together with or without Flag-Osx, HA-OsxK307R-K312R and Flag-HDAC4 expression plasmids. Relative luciferase 
activities of A and B were measured 36 h after transfection and normalized to the β-gal activity. c. MC3T3 E1 cells were transfected 
with Flag-Osx and Flag-CBP-HA expression plasmids alone or together. 36 h after transfection, ALP, BSP, Col1a1 and OC mRNAs were 
measured using real-time PCR. β-Actin was used as the internal control. d. MC3T3 cells were treated with rhBMP-2 (100 ng/ml) for 24 h 
followed by TSA (20 nM) for 24 h or not. ChIP assay were performed to examine the levels of Osx on the promoter of ALP, BSP, Col1a1, 
and OC. Data are presented as a percentage of input after subtracting control IgG values. e. C2C12 cells were transfected with HA-
Osx(WT) or HA-OsxK307R-K312R expression plasmids. 36 h after transfection, ALP, BSP, Col1a1, and OC mRNAs were measured using real-
time PCR. β-Actin was used as the internal control. F. C2C12 cells were transiently transfected with empty RK2 vector, the HA-Osx(WT) 
plasmid or HA-OsxK307R-K312R mutants. 24 h after transfection, the cells were incubated with BMP2 (100 ng/ml). ALP activity was examined 
by ALP staining 4–5 days later, or mineralization was assessed using Alizarin Red staining 10-12 days later. Representative images of three 
independent experiments are shown (left panel). Quantification of ALP activity and mineralization is shown in the right panel. Results are 
the mean ± S.D. of three independent experiments; *P <0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
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the formation of hydrogen bonds [50]. Increasing a 
protein’s stability by acetylation might act through direct 
competition for ubiquitination of the same lysine residues 
or via other mechanisms that inhibit ubiquitin-dependent 
degradation [51, 52]. In our previous studies, we identified 
K58 and K230 as the ubiquitination sites of Osx, not K307 
and K312 [22]. We speculated that acetylation increases 
Osx protein stability via an indirect mechanism, such as 
influencing the interaction between the ubiquitination-
related enzymes and Osx by changing Osx’s conformation, 
thereby inhibiting ubiquitin-dependent degradation of Osx.
In summary, we demonstrated that Osx is acetylated 
and that this modification plays important roles in 
regulating the protein stability, DNA binding activity and 
transcriptional activity of Osx, as well as in osteoblast 
differentiation. Further studies are needed to understand 
which signals control the acetylation and deacetylation of 
Osx, as well as any crosstalk between acetylation and other 
post-translational modifications, such as phosphorylation 
and ubiquitination of Osx.
MAterIAls And MetHods
cell culture
Saos-2 cells were maintained in McCoy’s 5A 
medium supplemented with 10% fetal bovine serum 
(FBS). MC3T3-E1 cells were maintained in alpha 
minimum essential medium (α-MEM) supplemented 
with 10% FBS. HEK 293T cells were cultured in high 
glucose Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS. C2C12 cells were 
maintained in DMEM supplemented with 15% FBS. 
All cells were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and cultured 
in the presence of 100 units/ml penicillin and 100 µg/ml 
streptomycin at 37°C in 5% CO2.
Plasmids, chemicals and antibodies
pCMVβ-p300-myc, pCI-Flag-PCAF, pcDNA3β-
Flag-CBP-HA, pAdEasy-Flag-GCN5, pcDNA3.1-
Flag-HDAC1, pcDNA3.1-Flag-HDAC3, pcDNA3.1-
Flag-HDAC4, and pcDNA3.1-Flag-HDAC5 expression 
plasmids were obtained from Addgene (Cambridge, 
MA, USA). RK2-HA-Osx-GFP, RK2-HA-Osx(WT) and 
Lys (K) to Arg (R) mutants of Osx were generated as 
descripted previously [35]. The RK2-HA-OsxK307R-K312R 
mutant was generated using Fast Mutagenesis System 
(TransGen Biotech, Beijing, P. R. China) using RK2-
HA-Osx(WT) as a template. CHX, TSA and SAHA 
were purchased from Sigma Aldrich (St. Louis, MO, 
USA). Protease inhibitors were obtained from Roche 
Diagnostics (Mannheim, Germany). Recombinant BMP2 
was purchased from R&D Systems (Minneapolis, MN, 
USA). The anti-Osx antibody was obtained from Abcam 
(Cambridge, MA, USA). The anti-Flag antibody was 
obtained from Sigma. The anti-HA antibody was obtained 
from Roche (Roche Diagnostics, Indianapolis, IN, USA). 
The anti-acetylated-lysine antibodies (rabbit polyclonal 
antibody and mouse monoclonal antibody) were purchased 
from Cell Signaling Technology (Danvers, MA, USA). 
EasyBlot anti-Rabbit IgG Kit (Optimized for Prot A/G) 
was purchased from Genetex (Irvine, CA, USA). Antibody 
against β-actin, anti-rabbit, anti-rat and anti-mouse IgG 
antibody were obtained from Bioworld Technology 
(Minneapolis, MN, USA). Lipofectamine 2000, Goat anti-
rabbit IgG and Alexa Fluor 594 antibodies were purchased 
from Invitrogen (Carlsbad, CA, USA). EZ-ChIP kit and 
Protein-G agarose beads were from Millipore (Darmstadt, 
Germany).
Western blotting
Western blotting was performed as previously 
described [22, 23]. Briefly, cells were lysed in RIPA 
buffer plus protease inhibitors, separated via SDS-PAGE, 
transferred to PVDF membrane, immunoblotted, and 
detected with the ECL reagent.
Co-immunoprecipitation (Co-IP) assay
HEK 293T cells were co-transfected with HA-Osx-
GFP and pcDNA3β-Flag-CBP-HA or pcDNA3-Flag-
HDAC4 expression plasmids. After 48 h of transfection, 
cells were washed twice with ice-cold phosphate-buffered 
saline (PBS) and then lysed with RIPA buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS). The cell lysates were 
incubated with anti-HA, anti-Osx or anti-Flag antibody 
at 4°C overnight. The mixture was then incubated with 
protein-G agarose beads at 4°C for 4 h. The beads were 
collected and washed three times by RIPA buffer. The 
beads were resuspended in SDS gel-loading buffer and 
analyzed by immunoblotting with anti-HA or anti-Flag 
antibodies.
For Co-IP of endogenous proteins, Saos-2 cells were 
treated with or without TSA (60 nM) for 24 h and then 
were lysed. The Co-IP was performed as above using anti-
Osx antibody (rabbit polyclonal antibody) to precipitate 
the immunocomplexes and the anti-Acetylated-Lysine 
antibody (mouse monoclonal antibody) to perform western 
blot analysis.
Immunofluorescence and confocal microscopy
HEK 293T cells were plated onto a six-well plate 
with glass bottom inserts. The cells were co-transfected 
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with HA-Osx-GFP and Flag-CBP-HA or Flag-HDAC4 
expression plasmids. 30 h after transfection, the cells 
were fixed with 4% paraformaldehyde for 20 min at room 
temperature. After washing twice with PBS, the cells 
were permeabilized with PBS containing 0.5% Triton 
X-100 for 10 min at 4°C, then treated with blocking buffer 
containing 4% bovine serum albumin (BSA) for 45 min 
at room temperature. Immunostaining was conducted 
with anti-Flag antibody overnight at 4°C, followed by 
Alexa Fluor 594-conjugated secondary antibodies for 1 h 
at room temperature. Finally, the cells were mounted in 
90% glycerol containing 4, 6-diamidino-2-phenylindole 
(DAPI), and examined using a confocal laser-scanning 
microscope (Zeiss LSM710). The images were analyzed 
using ZEN2011 software.
eMsA
Nuclear extracts of transfected HEK 293T cells 
were prepared using NE-PER Nuclear and Cytoplasmic 
Extraction Reagents and HaltTM Protease Inhibitor 
Cocktail Kit (Pierce Biotechnology, Rockford, IL, 
USA), as recommended by the manufacturer. EMSA 
were performed using the Gel Shift Assay System 
(Promega Corp., Madison, WI, USA) according to the 
instructions of the manufacturer. Oligonucleotide probes 
were annealed and labeled with [r-32P] ATP and T4-
polynucleotide kinase (NEB, Ipswich, MA, USA). Nuclear 
extracts of cells were incubated with the 32P-labeled 
probe in a total volume of 10 µl, as recommended by 
the manufacturer. The protein–DNA complexes were 
separated by 5% PAGE. Signals were recorded on X-ray 
film. The sequence of the oligonucleotide containing 
an Osx-binding sequence from the MMP-13 promoter 
was as follows: 5′-AGGAAGTTAACACACACCCC 
AAAGTGGTGACTCATC-3’. For the supershift 
experiments, anti-Flag antibody was added during pre-
incubation.
Luciferase reporter assay
HEK 293T cells were co-transfected with the hOc-
Luc reporter, β-gal expression vector, the Flag-Osx and 
Flag-CBP-HA or Flag-HDAC4 expression plasmids. After 
36 h of transfection, luciferase activity was measured using 
the Luciferase Reporter System (Promega), according to 
the manufacturer’s protocol. Relative luciferase activity 
was calculated by dividing the firefly luciferase activity 
by the β-gal activity.
real-time Pcr
Total RNA was isolated from cells using the TRIzol 
reagent (Invitrogen), according to the manufacturer’s 
protocol. Visualization of the ribosomal bands on a 
1% TAE agarose gel was used to assess RNA integrity. 
cDNA was synthesized from 1 µg of total RNA using the 
PrimeScript™ RT reagent kit with gDNA Eraser (Takara 
Biotechnology, Dalian, China). Real-time PCR was 
carried out using the ABI 7500 Real-time PCR system 
(Applied Biosystems). The reactions (20 µl) contained 
cDNA, forward and reverse primers and SYBR Premix 
Ex Taq™ II (Tli RNaseH Plus) (Takara). The amplification 
conditions were 95°C for 2 min, followed by 40 cycles of 
denaturation at 95°C for 15 s, and annealing and extension 
at 60°C for 1 min. The following primers were used: 
ALP, Forward: 5’-TGACCTTCTCTCCTC-CATCC-3’, 
Reverse: 5’-CTTCCTGGGAGTCTCATCCT-3’; Colla 
1, Forward: 5’-GCAACAGTCGCTTCACCTACA-3’, 
Reverse:5’-CAATGTCCAAGGGAGCCACAT-3’; 
OC, Forward: 5’-TGCTTGTGACGAGCTATCAG-3’, 
Reverse: 5’-GAGGACAGGGAGGATCAAG T-3’; BSP, 
Forward: 5’-AAGCAGCACCGTTGAGTATGG-3’; 
Reverse: 5’-CCTTGTAGTAGCTGTATTCGTCCTC-3’; 
β-actin, Forward: 5’-AGATGTGGATCAGCAAGCAG-3’, 
Reverse: 5’-GCGCAAGTTAGGTTTTGTCA-3’. 
Expression values were normalized to the value for 
β-actin.
chIP assay
ChIP was performed using the EZ-ChIP kit according 
to the manufacturer’s protocol. Briefly, MC3T3 E1 cells 
were treated with rhBMP-2 (100 ng/ml) for 24 h followed 
by TSA (20 nM) for 24 h. The cells were then harvested 
and chemically cross-linked with 1% formaldehyde for 10 
min at room temperature. After washing with cold PBS, 
the cells were lysed, sonicated, and immunoprecipitated 
with anti-Osx or rabbit-IgG antibodies pre-absorbed 
with 40 μl of protein A/G beads overnight at 4°C. After 
several washes, the complexes were eluted and the 
crosslinking was reversed by incubation at 65°C for 2 
h, then extracted (input) and immunoprecipitated DNA 
was purified. Real-time PCR was performed with the 
primers corresponded to the promoter regions of ALP, 
BSP, Col1a1 and OC as follows: ALP promoter primers: 
forward,5’-CCTGCCTGTTGCAGCCCTACG-3’, 
reverse,5’-TAAGGAGCGCAGTGGCGGGA-3’; 
BSP promoter primers: forward, 
5’-CTCTTGGCATCAACTCATTTCCTA-3’, reverse, 
5’-GAGAAGATGGTAGTTAGAGTTCTG-3’; 
Col1a1 promoter primers: forward, 
5’-AAGGGGTATTCTCTACCCACACTC-3’, reverse, 
5’-CAGCCAATCAGAACTGCCTGG-3’; OC promoter 
primers: forward, 5’-GAGCTGGCAGTCTCCGATTG-3’, 
reverse, 5’-GCTCTCTGATGTAAGCAGGAGG-3’.
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AlP staining
C2C12 cells seeded in 24-well plates were 
transfected with RK2-HA-Osx(WT), RK2-HA-OsxK307R-
K312R or RK2 empty vector using Lipofectamine 2000. At 
24 h after transfection, the cells were treated with BMP2 
(100 ng/ml) for 4–5 days. Before staining, the transfected 
C2C12 cells were fixed in 10% paraformaldehyde for 10 
min at room temperature. After washing with PBS, the 
cells were stained with 300 µg/ml of BCIP/NBT solution 
for 20 min; alkaline phosphatase-positive cells stained 
blue/purple.
Mineralization assay: alizarin red staining (ARS)
C2C12 cells seeded in 24-well plates were 
transfected with RK2-HA-Osx(WT), RK2-HA-OsxK307R-
K312R or RK2 empty vector using Lipofectamine 2000. At 
24 h after transfection, the cells were treated with BMP2 
(100 ng/ml) for 10–12 days. After the cells were fixed in 
5% paraformaldehyde for 10 min, the cells were stained 
with 2% ARS (pH 7.2) for 15 min and then washed 
twice with PBS. The orange and red areas were scored as 
calcium nodules.
statistical analysis
Results are expressed as the mean ± S.D. Student’s 
t-test and analysis of variance (ANOVA) were used to 
assess differences; P<0.05 was considered statistically 
significant.
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